Cover Image

Distinct roles of UVRAG and EGFR signaling in skeletal muscle homeostasis

Objective: Autophagy is a physiological self-eating process that can promote cell survival or activate cell death in eukaryotic cells. In skeletal muscle, it is important for maintaining muscle mass and function that is critical to sustain mobility and regulate metabolism. The UV radiation resistanc...

Full description

Saved in:

Bibliographic Details
Main Authors:	Min Jeong Kim (Author), Daniella Febbraro (Author), Sofia Farkona (Author), Taylor Gillmore (Author), Joe Eun Son (Author), Romario Regeenes (Author), Huntley H. Chang (Author), Evan Pollock-Tahiri (Author), Jiaqi Yang (Author), Yoo Jin Park (Author), Tharini Sivasubramaniyam (Author), Soo Jung Oh (Author), Punit Saraon (Author), Igor Stagljar (Author), Jonathan V. Rocheleau (Author), Chi-Chung Hui (Author), Isabella Caniggia (Author), Zhenyu Hao (Author), Tak W. Mak (Author), Ana Konvalinka (Author), Minna Woo (Author)
Format:	Book
Published:	Elsevier, 2021-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

VPS38/UVRAG and ATG14, the variant regulatory subunits of the ATG6/Beclin1-PI3K complexes, are crucial for the biogenesis of the yolk organelles and are transcriptionally regulated in the oocytes of the vector Rhodnius prolixus.
by: Priscila H Vieira, et al.
Published: (2021)

KOMUNIKASI TEKNOLOGI MASYARAKAT TEPAS TANDHA YEKTI KERATON YOGYAKARTA [TECHNOLOGY AND COMMUNITY COMMUNICATION FOSTERED BY TEPAS TANDHA YEKTI IN THE YOGYAKARTA ROYAL PALACE]
by: Andreina Caniggia
Published: (2020)

Recent Progress in CFTR Interactome Mapping and Its Importance for Cystic Fibrosis
by: Sang Hyun Lim, et al.
Published: (2018)

EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
by: Guangjian Yang, et al.
Published: (2022)

A Journey in Science: "Not Lost in Translation"
by: Tak Mak
Published: (2016)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
by: Brian J. Thomas, et al.
Published: (2023)

EGFR-Targeted Photodynamic Therapy
by: Luca Ulfo, et al.
Published: (2022)

EGFR Mutation in Nasopharyngeal Carcinoma
by: Evren Uzun, et al.
Published: (2022)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019)

Targeted Delivery of 111In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody
by: Tatiana S. Karyagina, et al.
Published: (2020)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)

Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification
by: Dekanić Andrea, et al.
Published: (2011)

EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy
by: Mauro Moroni, et al.
Published: (2011)

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
by: Colleen M. Britain, et al.
Published: (2018)

Knockout of c‐Cbl slows EGFR endocytic trafficking and enhances EGFR signaling despite incompletely blocking receptor ubiquitylation
by: Brandon L. M. Crotchett, et al.
Published: (2021)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

Structural analysis of cannabinoids against EGFR-TK leads a novel target against EGFR-driven cell lines
by: Thomanai Lamtha, et al.
Published: (2022)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
by: Ki-Chang Lee, et al.
Published: (2021)

4-Aryl-N-phenylpyrimidin-2-amines targeting EGFR-tyrosine kinase attenuated EGFR-expressing cell lines
by: Lueacha Tabtimmai, et al.
Published: (2022)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)

Targeting EGFR and Monitoring Tumorigenesis of Human Lung Cancer Cells In Vitro and In Vivo Using Nanodiamond-Conjugated Specific EGFR Antibody
by: Yu-Wei Lin, et al.
Published: (2022)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC
by: Fabio Villa
Published: (2015)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015)

Discovery of potent allosteric antibodies inhibiting EGFR
by: Léxane Fournier, et al.
Published: (2024)

EGFR Amplification and Glioblastoma Stem-Like Cells
by: Katrin Liffers, et al.
Published: (2015)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
by: Zesheng Li, et al.
Published: (2023)

Discordant EGFR mutation results: A case report
by: Ullas Batra, et al.
Published: (2022)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
by: Yue Zeng, et al.
Published: (2022)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023)

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy
by: Minhye Kim, et al.
Published: (2021)

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
by: Julie M. Janssen, et al.
Published: (2022)

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
by: Wilken Jason A, et al.
Published: (2010)

EGFR inhibitors-related panniculitis: A new side effect
by: Sofia Lopes, et al.
Published: (2019)

The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment
by: Felicity MacDonald, et al.
Published: (2017)

Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11
by: Benedikt Judmann, et al.
Published: (2023)

EGFR of platelet regulates macrophage activation and bacterial phagocytosis function
by: Shuhua Luo, et al.
Published: (2024)